A 70-Year-Old Woman with 10 Years of Markedly Elevated Alpha-Fetoprotein Measurements

Sherry X Hsu; Abby B Siegel; Paul D Berk

doi:10.1055/s-0030-1247136

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2010; 30(1): 099-106
DOI: 10.1055/s-0030-1247136

DIAGNOSTIC PROBLEMS IN HEPATOLOGY

A 70-Year-Old Woman with 10 Years of Markedly Elevated Alpha-Fetoprotein Measurements

Sherry X. Hsu¹ , Abby B. Siegel² , Paul D. Berk³

¹Department of Hematology and Oncology, New York, New York
²Hepatobiliary Oncology Unit, Center for Liver Disease and Transplantation, New York, New York
³Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York

Abstract

ABSTRACT

The incidence of hepatocellular carcinoma (HCC) is growing dramatically in the Western world. It is currently the fifth most common cancer worldwide, and the third most common cause of death from cancer. Studies clearly demonstrate that surveillance programs can increase the proportion of HCCs that are detected at an early stage, and improved therapeutic modalities, applied to early stage HCCs, improve cure rates and duration of survival in noncurable cases. What constitutes appropriate surveillance remains an unresolved issue. Measurements of serum α-fetoprotein and imaging, especially with ultrasound, are the most widely used elements in surveillance programs. The authors present a 70-year-old woman with chronic hepatitis C in whom elevated α-fetoprotein levels were first detected 10 years ago, reaching levels of >700 ng/mL. Frequent imaging studies by ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) have found only one lesion, which does not have radiographic features strongly suggestive of HCC. This lesion has been seen only intermittently, and when seen has shown no growth over an 8-year period. Segmental ablation did not alter the serum α-fetoprotein levels. The authors believe the patient does not have HCC. Alpha-fetoprotein as a screening test for HCC is known to lead to false-negative results. This case, and a review of the literature, emphasize that it is also subject to false-positives. In addition, interpretation of borderline imaging studies such as occurred in this case often causes controversy among the physicians involved. This case illustrates yet again the deficiencies of α-fetoprotein as a surveillance tool for HCC. It also highlights the need for more emphasis on developing new and improved tools for HCC surveillance if improved therapeutic modalities are to be exploited to the fullest.

KEYWORDS

Chronic hepatitis - hepatocellular carcinoma - cancer surveillance - biomarkers

Volltext

Referenzen

REFERENCES

1 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases . Management of hepatocellular carcinoma. Hepatology. 2005; 42(5) 1208-1236
2 Gupta A A, Kim D C, Krinsky G A, Lee V S. CT and MRI of cirrhosis and its mimics. AJR Am J Roentgenol. 2004; 183(6) 1595-1601
3 Eleftheriou N, Heathcote J, Thomas H C, Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J Clin Pathol. 1977; 30(8) 704-708
4 Chen D S, Sung J L. Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. Cancer. 1979; 44(3) 984-992
5 Tai W C, Hu T H, Wang J H et al.. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc. 2009; 108(3) 210-218
6 Hu K Q, Kyulo N L, Lim N, Elhazin B, Hillebrand D J, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004; 99(5) 860-865
7 Peng Y C, Chan C S, Chen G H. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999; 46(30) 3208-3211
8 Fung J, Lai C L, Yuen M F. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect. 2009; 15(11) 964-970
9 Zhang B H, Yang B H, Tang Z Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7) 417-422
10 Kemmer N, Neff G, Kaiser T et al.. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl. 2006; 12(10) 1519-1522
11 Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008; 25(10) 1075-1084
12 Vij K, Wang H L. Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence. Int J Surg Pathol. 2008; 16(2) 194-198
13 Bae J S, Park S J, Park K B et al.. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med. 2005; 20(1) 80-85
14 Sell S, Nichols M, Becker F F, Leffert H L. Hepatocyte proliferation and alpha 1-fetoprotein in pregnant, neonatal, and partially hepatectomized rats. Cancer Res. 1974; 34(4) 865-871
15 Sell S. Heterogeneity of alpha-fetoprotein (AFP) and albumin containing cells in normal and pathological permissive states for AFP production: AFP containing cells induced in adult rats recapitulate the appearance of AFP containing hepatocytes in fetal rats. Oncodev Biol Med. 1980; 1(2) 93-105
16 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112(2) 463-472
17 Sato Y, Nakata K, Kato Y et al.. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993; 328(25) 1802-1806
18 Di Bisceglie A M, Sterling R K, Chung R T HALT-C Trial Group et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005; 43(3) 434-441
19 Chu C, Hwang S, Luo J et al.. Clinical, virological, immunological, and pathological significance of GB virus C/hepatitis G infection in patients with chronic hepatitis C. Hepatol Res. 2001; 19(3) 225-236
20 Nguyen M H, Keeffe E B. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002; 35(5, Suppl 2) S86-S91
21 Nguyen M H, Garcia R T, Simpson P W, Wright T L, Keeffe E B. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002; 36(2) 410-417
22 Lok A S, Lai C L. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989; 9(1) 110-115
23 Trevisani F, D'Intino P E, Morselli-Labate A M et al.. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34(4) 570-575
24 Chan S L, Mo F K, Johnson P J et al.. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009; 27(3) 446-452
25 Daniele B, Bencivenga A, Megna A S, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127(5, Suppl 1) S108-S112
26 Farinati F, Marino D, De Giorgio M et al.. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol. 2006; 101(3) 524-532
27 Sato T, Tateishi R, Yoshida H et al.. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009; 3(4) 544-550
28 Tong M J, Blatt L M, Kao V W. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001; 16(5) 553-559
29 El-Serag H B, Marrero J A, Rudolph L, Reddy K R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6) 1752-1763
30 Benson III A B, Abrams T A, Ben-Josef E et al.. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7(4) 350-391
31 Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009; 137(1) 26-29
32 Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001; 34(4) 603-605
33 Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006; 12(8) 1175-1181
34 Khien V V, Mao H V, Chinh T T et al.. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers. 2001; 16(2) 105-111
35 Marrero J A, Su G L, Wei W et al.. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37(5) 1114-1121
36 Marrero J A, Feng Z, Wang Y et al.. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137(1) 110-118
37 Volk M L, Hernandez J C, Su G L, Lok A S, Marrero J A. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007; 3(2) 79-87
38 Gomaa A I, Khan S A, Leen E L, Waked I, Taylor-Robinson S D. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009; 15(11) 1301-1314
39 Llovet J M, Di Bisceglie A M, Bruix J Panel of Experts in HCC-Design Clinical Trials et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(10) 698-711
40 Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010; 30(1) 3-16
41 Gannon C J, Izzo F, Aloia T A et al.. Can hepatocellular cancer screening increase the proportion of long-term survivors?. Hepatogastroenterology. 2009; 56(93) 1152-1156
42 Mendizabal M, Reddy K R. Current management of hepatocellular carcinoma. Med Clin North Am. 2009; 93(4) 885-900, viii , viii
43 Cheng A L, Kang Y K, Chen Z et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1) 25-34
44 Llovet J M, Ricci S, Mazzaferro V SHARP Investigators Study Group et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4) 378-390
45 Patel D, Terrault N A, Yao F Y, Bass N M, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2005; 3(1) 75-84

Paul D BerkM.D. F.A.C.P.

Division of Digestive and Liver Diseases, Columbia University Medical Center

Russ Berrie Medical Science Pavilion, 1150 Saint Nicholas Avenue, Room 412, New York, NY 10032

eMail: pb2158@columbia.edu